Onychomycosis has been a consistent topic at podiatric and dermatology conferences since the first truly effective FDA approved oral antifungal, terbinafine, was approved in the late 1990s. Therapeutically, the major change in the intervening 20 years has been the approvals of the prescription topical therapies; ciclopirox lacquer, effinaconazole solution and tavaborole solution. Dr. Joseph will present topics that traditionally have not been discussed in detail in the majority of onychomycosis presentations. These include the emergence of antifungal resistance, primarily to the previous “Gold Standard” antifungal terbinafine, some unique aspects of the molecular diagnosis of fungal infections, and, finally, examine the evidence for the use of over-the-counter topical antifungal products that are available at local pharmacies and being dispense in podiatrist’s offices.
Complete the 4 steps to earn your CE/CME credit:
Release Date: 04/07/2023 Expiration Date: 04/07/2024
To view Lectures online, the following specs are required:
It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems sponsored programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.---
Warren Joseph has disclosed that he is a consultant/speaker's bureau for Ortho Dermatologics; an advisor to Paratek.